Skip to content

AKI Prevention and Early Intervention in Patients Undergoing VAD Placement

AKI Prevention and Early Intervention in Patients Undergoing VAD Placement

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03236831
Enrollment
210
Registered
2017-08-02
Start date
2017-04-11
Completion date
2019-02-17
Last updated
2019-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Injury

Keywords

Ventricular Assist Device

Brief summary

The investigators are doing this research to find out if more careful assessment and elimination of potential risk factors of acute kidney injury (AKI) during the subject's perioperative period will reduce their chance of kidney damage and kidney damage related problems.

Detailed description

The purpose of the study is to investigate whether preventive measures for patients undergoing ventricular assist device (VAD) placement will reduce AKI occurrence, progression and associated complications. Participants will be in the study for a total of 6 days (1 day prior to the surgery and 5 days after the surgery). The investigators will review the participant's medical record up to one year after surgery. The study investigators will access the participant's electronic medical record 24 hours prior to the planned VAD implantation and review the participant's medication regimen and provide recommendations to the participant's primary care physician in an effort to minimize potential risks for AKI. There will be no intervention during the operation. The clinical recommendations will cover the following: 1. Avoidance of potentially nephrotoxic agents. 2. Optimizing volume status (avoidance of volume overload or depletion) 3. Optimizing electrolytes and acid-base status 4. Minimizing IV contrast exposure when appropriate 5. Treating severe anemia 6. Optimization of hemodynamics (Mean arterial BP\>65mmHg). The investigators plan to compare the results of this study with the historical data in the same patient population in the years of 7/1/2015-6/30/2017.

Interventions

The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following: 1. Avoidance of potentially nephrotoxic medications. 2. Optimizing volume status (avoidance of volume overload or depletion) 3. Optimizing electrolytes and acid-base status 4. Minimizing IV contrast exposure when appropriate 5. Treating severe anemia 6. Optimization of hemodynamics (Mean arterial BP\>65mmHg)

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Open label single group interventional study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients that will undergo VAD placement. * Patients able to give consent

Exclusion criteria

* Patients on dialysis (hemodialysis or peritoneal dialysis) * Non-elective VAD placement (VAD implantation decision made within 24 hours)

Design outcomes

Primary

MeasureTime frameDescription
Rate of postoperative AKI (within 5 post-op days) based on AKIN criteria5 days after the surgeryThe Acute Kidney Injury Network (AKIN) staging system has 3 stages: 1) serum creatinine increase ≥ 26.5 umol/L or increase to 1.5-2.0 fold from baseline, OR urine output \<0.5 ml/kg/h for 6 h; 2) serum creatinine increase \> 2.0-3.0 fold from baseline OR urine output \<0.5 ml/kg/h for 12 h; 3) serum creatinine increase \>3.0 fold from baseline OR serum creatinine ≥354 umol/l with an acute increase of at least 44 umol/l or need for Renal Replacement Therapy (RRT) OR urine output \<0.3 ml/kg/h for 24 h OR anuria for 12 OR need for RRT

Secondary

MeasureTime frameDescription
Severity of postoperative AKI (within 5 post-op days) based on AKIN criteria5 days after the surgeryThe AKIN staging system has 3 stages: 1) serum creatinine increase ≥ 26.5 umol/L or increase to 1.5-2.0 fold from baseline, OR urine output \<0.5 ml/kg/h for 6 h; 2) serum creatinine increase \> 2.0-3.0 fold from baseline OR urine output \<0.5 ml/kg/h for 12 h; 3) serum creatinine increase \>3.0 fold from baseline OR serum creatinine ≥354 umol/l with an acute increase of at least 44 umol/l or need for Renal Replacement Therapy (RRT) OR urine output \<0.3 ml/kg/h for 24 h OR anuria for 12 OR need for RRT
Length of hospital stay1 year after the surgeryThe length of hospital stay will be determined from the electronic medical record.
In hospital (perioperative) mortality and one-year mortalityApproximately 5 days after surgery, one year after enrollmentThe number of subjects who died in hospital (perioperatively) and one year after surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026